FAST Diagnostics

FAST’s patented technology provides rapid and accurate surveillance of true kidney function for use in hospitals, intensive care units, organ transplant units, clinical trials, drug development, and physician offices. The FAST GFR system™ enables healthcare providers with a sensitive tool to move from delayed estimates of Glomerular Filtration Rate (eGFR) to measured GFR in real-time (mGFR). This will significantly aid them in improving outcomes for millions of patients with acute kidney failure and chronic kidney disease.

The FDA has determined FAST meets the requirements for a rare Expedited Review due to the agency's assessment that this is “breakthrough technology” addressing a significant unmet clinical need, with the potential for "a clinically meaningful advantage over existing technology." This tool is revolutionary in the early detection and treatment of Acute Kidney Injury (AKI), the titration of AKI therapies, as well as the dosing of nephrotoxic drugs. This tool can also enable better stratification and monitoring of clinical trial patients, as well as improve outcomes in kidney transplantation.

FAST's point of care device is what experts are asking for to serve an unmet $1.5B need in the initial European and U.S. Intensive Care market alone.

The size of the unmet medical need in this single market, as well as FAST's unique positioning to address it, was confirmed by an independent market research report funded by a then potential, and now current investor.

To learn more about FAST, please visit www.fastdiagnostics.com.